CN101208310A - 新晶型4-[6-甲氧基-7-（3-哌啶-1-基-丙氧基）喹唑啉-4-基]哌嗪-1-羧酸（4-异丙氧基苯基）-酰胺 - Google Patents

新晶型4-[6-甲氧基-7-（3-哌啶-1-基-丙氧基）喹唑啉-4-基]哌嗪-1-羧酸（4-异丙氧基苯基）-酰胺 Download PDF

Info

Publication number
CN101208310A
CN101208310A CNA2006800232271A CN200680023227A CN101208310A CN 101208310 A CN101208310 A CN 101208310A CN A2006800232271 A CNA2006800232271 A CN A2006800232271A CN 200680023227 A CN200680023227 A CN 200680023227A CN 101208310 A CN101208310 A CN 101208310A
Authority
CN
China
Prior art keywords
sulfate
pharmaceutical composition
crystalline form
type
vitriol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800232271A
Other languages
English (en)
Chinese (zh)
Inventor
克雷格·格兰特
霍阿·Q·卢昂
马克·D·安吉利诺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of CN101208310A publication Critical patent/CN101208310A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2006800232271A 2005-07-20 2006-07-20 新晶型4-[6-甲氧基-7-（3-哌啶-1-基-丙氧基）喹唑啉-4-基]哌嗪-1-羧酸（4-异丙氧基苯基）-酰胺 Pending CN101208310A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70092605P 2005-07-20 2005-07-20
US60/700,926 2005-07-20

Publications (1)

Publication Number Publication Date
CN101208310A true CN101208310A (zh) 2008-06-25

Family

ID=37188923

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800232271A Pending CN101208310A (zh) 2005-07-20 2006-07-20 新晶型4-[6-甲氧基-7-（3-哌啶-1-基-丙氧基）喹唑啉-4-基]哌嗪-1-羧酸（4-异丙氧基苯基）-酰胺

Country Status (7)

Country Link
US (1) US20100179162A1 (enExample)
EP (1) EP1904459A1 (enExample)
JP (1) JP2009502804A (enExample)
CN (1) CN101208310A (enExample)
AU (1) AU2006269917A1 (enExample)
CA (1) CA2612459A1 (enExample)
WO (1) WO2007012042A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109549941A (zh) * 2017-09-26 2019-04-02 广西梧州制药（集团）股份有限公司 一种吡唑并嘧啶衍生物在制备治疗疾病药物方面的用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100273808A1 (en) * 2008-11-21 2010-10-28 Millennium Pharmaceticals, Inc. Lactate salt of 4-[6-methoxy-7-(3-piperidin-1-yl-propoxy)quinazolin-4-yl]piperazine-1-carboxylic acid(4-isopropoxyphenyl)-amide and pharmaceutical compositions thereof for the treatment of cancer and other diseases or disorders
JP2014513044A (ja) * 2011-02-10 2014-05-29 マイラン ラボラトリーズ リミテッド ホスアンプレナビルカルシウム結晶およびその調製方法
WO2015009889A1 (en) 2013-07-18 2015-01-22 Concert Pharmaceuticals, Inc. Deuterated intedanib derivatives and their use for the treatment of proliferative disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US642376A (en) * 1898-10-24 1900-01-30 John W Skilton Car-axle box.
WO1998014431A1 (en) * 1996-10-01 1998-04-09 Kyowa Hakko Kogyo Co., Ltd. Nitrogenous heterocyclic compounds
JP3011904B2 (ja) * 1997-06-10 2000-02-21 明久 井上 金属ガラスの製造方法および装置
EP1309568B1 (en) * 2000-08-18 2011-02-16 Millennium Pharmaceuticals, Inc. [(quinazolin-4-yl)piperazin-4-yl]thiocarboxamide compounds as inhibitors of the phosphorylation of a PDGF receptor
MXPA03001359A (es) * 2000-08-18 2004-12-13 Millennium Pharm Inc Derivados de quinazolina como inhibidores de cinasa.
WO2002016362A2 (en) * 2000-08-18 2002-02-28 Cor Therapeutics, Inc. Nitrogenous heterocyclic compounds
ATE502928T1 (de) * 2000-11-01 2011-04-15 Millennium Pharm Inc Stickstoffhaltige heterozyklische verbindungen und verfahren zu deren herstellung
US20040259881A1 (en) * 2001-02-02 2004-12-23 Anjali Pandey Nitrogenous heterocyclic compounds
AU2002254152A1 (en) * 2001-03-08 2002-09-24 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
US7456189B2 (en) * 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109549941A (zh) * 2017-09-26 2019-04-02 广西梧州制药（集团）股份有限公司 一种吡唑并嘧啶衍生物在制备治疗疾病药物方面的用途

Also Published As

Publication number Publication date
CA2612459A1 (en) 2007-01-25
JP2009502804A (ja) 2009-01-29
AU2006269917A1 (en) 2007-01-25
EP1904459A1 (en) 2008-04-02
US20100179162A1 (en) 2010-07-15
WO2007012042A1 (en) 2007-01-25

Similar Documents

Publication Publication Date Title
CN100404032C (zh) 新型晶形抗癌化合物zd1839
JP6928986B2 (ja) キナーゼ活性を阻害するためのインダゾール系化合物、その組成物および使用
JP2015017116A (ja) 癌および他の疾患または障害の処置のための、４−［６−メトキシ−７−（３−ピペリジン−１−イル−プロポキシ）キナゾリン−４−イル］ピペラジン−１−カルボン酸（４−イソプロポキシフェニル）−アミドの乳酸塩およびその薬学的組成物
JP3763414B2 (ja) Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
JP2013522232A (ja) Ｎ−［３−フルオロ−４−（｛６−（メチロキシ）−７−［（３−モルホリン−４−イルプロピル）オキシ］−キノリン−４−イル｝オキシ）フェニル］−ｎ’−（４−フルオロフェニル）シクロプロパン−１，１−ジカルボサミドの水和結晶性形状
CN107873029A (zh) 依鲁替尼与羧酸的共晶体
CN113966332B (zh) Cdk9抑制剂的多晶型物及其制法和用途
KR20240000540A (ko) (s)-n-(3-(2-(((r)-1-하이드록시프로판-2-일)아미노)-6-모르폴리노피리딘-4-일)-4-메틸페닐)-3-(2,2,2-트리플루오로에틸)피롤리딘-1-카르복스아미드 및 이의 염의 고체 상태 형태
TWI870440B (zh) 活化素受體樣激酶抑制劑之鹽及晶體形式
CN106279126B (zh) 阿法替尼酸加成盐及其晶型、其制备方法及药物组合物
CN102066362A (zh) 二氢吲哚酮衍生物
CN101208310A (zh) 新晶型4-[6-甲氧基-7-（3-哌啶-1-基-丙氧基）喹唑啉-4-基]哌嗪-1-羧酸（4-异丙氧基苯基）-酰胺
TW201920160A (zh) ２－（５－（４－（２－嗎啉乙氧基）苯基）吡啶－２－基）－ｎ－芐乙醯胺之固態形式
CN111606887B (zh) 一种新型激酶抑制剂
JP7743028B2 (ja) キナーゼ阻害剤として使用される化合物およびその使用
JP7702752B2 (ja) チアゾール－ラクタム－スピロ複素環化合物及びその適用
TW202342466A (zh) 二肽基肽酶抑制劑化合物的鹽及晶型
CN116854694B (zh) [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用
WO2021036814A1 (zh) 吡唑衍生物及其用途
CN101228150A (zh) 4-甲基-n-[3-（4-甲基-咪唑-1-基）-5-三氟甲基-苯基]-3-（4-吡啶-3-基-嘧啶-2-基氨基）-苯甲酰胺的晶形
TWI809330B (zh) Cdk9抑制劑的多晶型物及其製法和用途
HK40100623A (zh) [1，2，4]三唑[4，3-b]哒嗪化合物的晶型及其制备方法和应用
HK40100623B (zh) [1，2，4]三唑[4，3-b]哒嗪化合物的晶型及其制备方法和应用
WO2025007275A1 (zh) [1,2,4]三唑[4,3-b]哒嗪化合物的晶型及其制备方法和应用
TW202416984A (zh) 化合物i或其鹽的固體形式

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20080625